ES2627011T3 - Variantes de corte y empalme específicas de metástasis de Mena y usos de las mismas en el diagnóstico, pronóstico y tratamiento de tumores - Google Patents
Variantes de corte y empalme específicas de metástasis de Mena y usos de las mismas en el diagnóstico, pronóstico y tratamiento de tumores Download PDFInfo
- Publication number
- ES2627011T3 ES2627011T3 ES08713370.8T ES08713370T ES2627011T3 ES 2627011 T3 ES2627011 T3 ES 2627011T3 ES 08713370 T ES08713370 T ES 08713370T ES 2627011 T3 ES2627011 T3 ES 2627011T3
- Authority
- ES
- Spain
- Prior art keywords
- mena
- cells
- tumors
- seq
- metastases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 12
- 206010027476 Metastases Diseases 0.000 title description 7
- 238000003745 diagnosis Methods 0.000 title description 2
- 238000004393 prognosis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 101100225689 Mus musculus Enah gene Proteins 0.000 abstract description 17
- 230000014509 gene expression Effects 0.000 abstract description 10
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 230000002018 overexpression Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 26
- 239000013615 primer Substances 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 8
- 108700024394 Exon Proteins 0.000 description 8
- 230000009545 invasion Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000049398 Vasodilator-stimulated phosphoproteins Human genes 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108010059397 ENA-VASP proteins Proteins 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 101000877404 Homo sapiens Protein enabled homolog Proteins 0.000 description 2
- 241000269319 Squalius cephalus Species 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000001002 morphogenetic effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 1
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000048778 human Enah Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000025342 organ morphogenesis Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Un método para determinar si un sujeto tiene un tumor metastásico, que comprende analizar una muestra de sangre, tejido y/o tumor del sujeto en busca de la expresión de la variante ++ y/o +++ de Mena, en el que la expresión de la variante ++ y/o +++ de Mena se compara con la expresión de Mena 11a, y en el que la sobreexpresión de la variante ++ y/o +++ de Mena indica la presencia de un tumor metastásico.
Description
5
10
15
20
25
30
35
40
45
se llevó a cabo mediante el uso del programa informático ABI Prism 2.0 (Applied Biosystems, Foster City, CA). Se proporciona una estrategia para el diseño de las secuencias de los cebadores en la Figura 5.
RACE, Clonación y Secuenciación: El RACE de 3' y 5' se llevó a cabo mediante el uso del kit Invitrogen RACE Ready cDNA (las secuencias se proporcionan en la Tabla 1, y la estrategia de diseño de cebadores de RACE se proporciona en la Figura 5), y se clonaron mediante el uso del kit de clonación de Invitrogen TOPO TA, siguiendo el protocolo del fabricante. Brevemente, la PCR se llevó a cabo mediante el uso de dos cebadores internos para las secuencias ++ y +++ (Tabla 1) y un cebador de oligo dT para el extremo 5', y un cebador de poli G para el extremo 3'. Los productos de PCR se eluyeron del gel y se clonaron en el vector pCR-TOPO. El vector ligado se transformó en células químicamente competentes; los clones seleccionados se secuenciaron mediante el uso de cebadores M13. La alineación de secuencias se llevó a cabo mediante el uso del programa informático DNASTAR.
Tabla 1. Secuencias de Cebadores
Secuencias de cebadores de Mena
- 1.
- AGAGGATGCCAATGTCTTCG (SEQ ID Nº:5)
- 2.
- TGTCTAGGCAATGTTGGCC (SEQ ID Nº:6)
- 3.
- GATTCAAGACCATCAGGTTGTG (SEQ ID Nº:7)
- 4.
- CAATGTTGGCCCTAAATAGAA (SEQ ID Nº:8) d4. TTCTATTTAGGGCCAACATTG (SEQ ID Nº:9)
- 5.
- TACATCGCAAATTAGTGCTGTC (SEQ ID Nº:10) d5. GACAGCACTAATTTGCGATGT (SEQ ID Nº:11)
- 6.
- CCAACCAGAAAACCTTGGG (SEQ ID Nº:12)
- 7.
- TGCTTCAGCCTCTCATAGTCA (SEQ ID Nº:13)
- 8.
- GAGCGAGAGAGGCAGAG (SEQ ID Nº:14)
- 9.
- GCTCGGAAGCAGAGGAGTCT (SEQ ID Nº:15) Cebador Pan Mena Directo: CGGCAGTAAGTCACCTGTCA (SEQ ID Nº:16) Inverso: CTTCAGCTTTGCCAGCTCTT (SEQ ID Nº:17) Cebadores Smart Oligonucleótido SMART II™ A AAGCAGTGGTATCAACGCAGAGTACGCGGG (SEQ ID Nº:18) Cebador A de CDS de 3'-RACE AAGCAGTGGTATCAACGCAGAGTAC (T) 30V N (SEQ ID Nº:19) (N = A, C, G, o T; V = A, G, o C) Cebador A de CDS de 5'-RACE (T) 25V N (SEQ ID Nº:20) (N = A, C, G, o T; V = A, G, o C) Largo: CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT (SEQ ID Nº:21) Corto: CTAATACGACTCACTATAGGGC (SEQ ID Nº:22)
Resultados y Discusión
En este estudio se han identificado isoformas específicas de Mena que están elevadas en las células de cáncer de mama invasivo. Se utilizaron tres modelos en este informe, es decir, el modelo de aloinjerto de adenocarcinoma de ratas MTLn3, el modelo de cáncer de mama transgénico de ratones PyMT y varias líneas celulares de cáncer de mama humano. La expresión de Mena está elevada 3-4 veces en las células de cáncer de mama primarias invasivas (Wang et al., 2004). Los controles realizados para determinar los efectos de las manipulaciones usadas para recoger las células tumorales invasivas del tumor mamario primario demuestran que la expresión de la isoforma de invasión
7 5
15
25
35
45
55
de Mena no se induce por la recogida de las células. Solamente el microambiente del tumor induce la expresión de estas isoformas. En este estudio se determinó la estabilidad de esta sobreexpresión, es decir, las células invasivas recogidas mediante un análisis de invasión in vivo mostraron una elevación de 3-4 veces de la expresión de Mena en comparación con APTCs. Por lo tanto, las células se siguieron y se separaron de la sangre y de la metástasis pulmonar. Mediante el uso del modelo MTLn3 y del modelo transgénico PyMT de ratón, se recogieron las células invasivas y se separaron mediante un análisis de invasión in vivo, y las APTCs mediante clasificación por FACS. El análisis mediante RT-PCR de las células invasivas mostró que hubo amplicones específicos de los exones ++ y +++ elevados en ambos modelos. También se detectó un amplicón específico para el exón +. Sin embargo, no mostró ningún cambio entre las células invasivas y las APTCs. Los estudios mediante QRT-PCR confirmaron el hallazgo de la RT-PCR, y mostraron una elevación de los exones ++ y +++ en las células invasivas para el modelo de MTLn3 (Figura 1A) y para el modelo de PyMT de ratón (Figura 1B). La Figura 2 muestra que la variante de corte y empalme ++ y +++ del ARN mensajero de Mena permanece elevada en las células que se han intravasado a la sangre y en las células que han formado metástasis eficaces en el pulmón. Esto indica que el cambio del nivel de expresión se debe a un cambio genético estable en las células metastásicas.
Los resultados de la RT-PCR y la QRT-PCR mostraron que ambos exones ++ y +++ están elevados en las células invasivas. Sin embargo, no estuvo claro si los exones están presentes en un único transcrito o en transcritos diferentes. Para abordar esta cuestión, se clonaron y se secuenciaron los transcritos que albergaban ++ y +++ de los tumores transgénicos de ratón PyMT invasivos. Se seleccionó el análisis RACE para identificar los transcritos que contenían los exones ++ y +++. Los resultados proporcionan una secuencia consenso de al menos 10 clones para cada transcrito. Los resultados muestran un 100% de coincidencia con las secuencias publicadas de ratón, y demostraron que los exones ++ y +++ están en transcritos diferentes. Las alineaciones para las secuencias ++ y +++ se muestran en la Figura 4.
Las Figuras 6 y 7 muestran que las dos variantes 2+ y 3+ permanecen elevadas a nivel de mARN en las células tumorales circulantes en la sangre, lo que hace posible un análisis de sangre para estas variantes. Así, se puede usar una PCR, sondas de ácidos nucleicos y/o tinción con anticuerpos para diagnosticar una enfermedad metastásica mediante el uso de una muestra de sangre.
Basándose en los datos de alineación de secuencias anteriores, una sonda molecular, ácido nucleico o anticuerpo, o ambos, hacia cada variante ++ o +++ proporcionaría una herramienta de diagnóstico/pronóstico importante. Debido a que la estimulación de la expresión de los exones ++ y +++ observada aquí es un cambio estable en las células tumorales mamarias invasivas y metastásicas, las sondas dirigidas de manera específica hacia estos exones serían marcadores de diagnóstico potentes con respecto a la presencia de células metastásicas, y por lo tanto con respecto a la posibilidad de enfermedad metastásica.
La Figura 8 muestra el aumento de la migración de células tumorales cuando se expresa Mena 3+. De manera importante, como se muestra en la Figura 9, la inhibición de la migración de células tumorales metastásicas se da cuando se inhibe Mena, en este caso mediante el uso de mito, una molécula que redirige a Mena hacia un lugar erróneo en la célula. Este resultado establece que la inhibición de la función de Mena inhibe la migración de las células metastásicas, y por lo tanto es una buena estrategia para inhibir la metástasis.
Todos los adenocarcinomas humanos derivan de órganos epiteliales que pueden compartir una estrategia morfogenética común a nivel molecular (Condeelis y Pollard, 2006; Wang et al., 2004, 2005). La característica distintiva de la invasión, de la que Mena 2+ y 3+ son isoformas de invasión, predice que se usa la misma estrategia morfogenética para la morfogénesis normal de órganos y la metástasis tumoral. Esto sugiere que Mena 2+ y 3+ serán objetivos útiles para el diagnóstico y la terapia de todos los adenocarcinomas comunes en seres humanos adultos. En particular, la invención descrita en la presente memoria será aplicable a tumores tales como tumores de mama, próstata, páncreas, colon, cerebro e hígado.
Referencias
Barzik M, Kotova TI, Higgs HN et al. Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J Biol Chem. 5 de agosto de 2005; 280(31):28653-62.
Brinkman BM. Splice variants as cancer biomarkers. Clin Biochem. julio de 2004; 37(7):584-94.
Condeelis y Pollard (2006) Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell
124: 263-266.
Condeelis J, Singer RH, Segall JE. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol. 2005;21: 695-718.
Di Modugno F, Bronzi G, Scanlan MJ et al. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer. 10 de mayo de 2004; 109(6):909-18.
Gertler FB, Niebuhr K, Reinhard M et al. Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics. Cell. 18 de oct. de 1996; 87(2):227-39.
8
Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. julio de 2003; 9(7):2632-41.
Kuhnel K, Jarchau T, Wolf E et al. The VASP tetramerization domain is a right-handed coiled coil based on a 15residue repeat. Proc Natl Acad Sci USA. 7 de dic. de 2004; 101(49):17027-32.
5 Loureiro JJ, Rubinson DA, Bear JE et al. Critical roles of phosphorylation and actin binding motifs, but not the central proline-rich region, for Ena/vasodilator-stimulated phosphoprotein (VASP) function during cell migration. Mol Biol Cell. julio de 2002; 13 (7):2533-46.
Otsubo T, Iwaya K, Mukai Y, Mizokami Y, Serizawa H, Matsuoka T, Mukai K. Involvement of Arp2/3 complex in the process of colorectal carcinogenesis. Mod Pathol. abril de 2004; 17(4):461-7.
10 Prehoda KE, Lee DJ, Lim WA. Structure of the enabled/VASP homology 1 domain-peptide complex: a key component in the spatial control of actin assembly. Cell. 14 de mayo de 1999; 97(4):471-80.
Sambrook J y Russell DW. Molecular Cloning. A Laboratory Manual, tercera edición, Cold Spring Harbor Laboratory Press, 2001.
Scott JA, Shewan AM, den Elzen NR et al. Ena/VASP proteins can regulate distinct modes of actin organization at 15 cadherin-adhesive contacts. Mol Biol Cell. marzo de 2006; 17(3):1085-95.
Urbanelli L, Massini C, Emiliani C et al. Characterization of human Enah gene. Biochim Biophys Acta. ene.-feb. de 2006; 1759(1-2):99-107.
Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays. abril de 2006; 28(4):378-86.
Wang W, Goswami S, Lapidus K, et al. Identification and testing of a gene expression signature of invasive 20 carcinoma cells within primary mammary tumors. Cancer Res. 1 de dic. de 2004; 64(23):8585-94.
Wang, Goswami, Sahai, Wyckoff, Segall, Condeelis (2005) Tumor Cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol. 15:138-145.
Wang W, Mouneimne G, Sidani M et al., The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol. 8 de mayo de 2006; 173(3):395-404.
25 Wyckoff JB, Segall JE, Condeelis JS. The collection of the motile population of cells from a living tumor. Cancer Res. 1 de oct. de 2000; 60(19):5401-4.
9
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89930307P | 2007-02-02 | 2007-02-02 | |
US899303P | 2007-02-02 | ||
PCT/US2008/001343 WO2008097466A2 (en) | 2007-02-02 | 2008-01-31 | Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2627011T3 true ES2627011T3 (es) | 2017-07-26 |
Family
ID=39682291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08713370.8T Active ES2627011T3 (es) | 2007-02-02 | 2008-01-31 | Variantes de corte y empalme específicas de metástasis de Mena y usos de las mismas en el diagnóstico, pronóstico y tratamiento de tumores |
Country Status (6)
Country | Link |
---|---|
US (4) | US8603738B2 (es) |
EP (1) | EP2126566B1 (es) |
CA (1) | CA2676179C (es) |
DK (1) | DK2126566T3 (es) |
ES (1) | ES2627011T3 (es) |
WO (1) | WO2008097466A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2126566B1 (en) | 2007-02-02 | 2017-03-29 | Albert Einstein College of Medicine, Inc. | Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors |
US8642277B2 (en) * | 2009-09-10 | 2014-02-04 | Albert Einstein College Of Medicine Of Yeshiva University | Tumor microenvironment of metastasis (TMEM) and uses thereof in diagnosis, prognosis and treatment of tumors |
CA2788456A1 (en) * | 2010-01-27 | 2011-08-04 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for determining agents targeting mena isoforms and uses thereof for diagnosis and treatment of metastatic tumors |
US10114023B2 (en) | 2012-04-18 | 2018-10-30 | Massachusetts Institute Of Technology | Method of enhancing the efficacy of anti-hepatocyte growth factor receptor breast cancer therapy by administering an inhibitor of menaINV |
EP3193748B1 (en) | 2014-09-18 | 2020-07-01 | Mayo Foundation for Medical Education and Research | Soft tissue cutting device |
WO2016191401A1 (en) | 2015-05-27 | 2016-12-01 | Albert Einstein College Of Medicine, Inc. | Tmem active test and uses thereof in diagnosis, prognosis and treatment of tumors |
EP3373971A4 (en) * | 2015-11-13 | 2019-09-25 | Massachusetts Institute of Technology | METHOD AND COMPOSITIONS FOR THE DETECTION AND MODULATION OF CANCER CELLS |
WO2018009896A1 (en) | 2016-07-08 | 2018-01-11 | Metastat, Inc. | Methods and compositions for anticancer therapies that target mena protein isoforms kinases |
US11802875B2 (en) | 2017-05-30 | 2023-10-31 | Albert Einstein College Of Medicine | Method for treating neoadjuvant chemotherapy-induced metastasis |
US10864055B2 (en) | 2017-10-13 | 2020-12-15 | Sonex Health, Inc. | Tray for a soft tissue cutting device and methods of use |
WO2019126112A1 (en) * | 2017-12-19 | 2019-06-27 | Albert Einstein College Of Medicine, Inc. | Combined markers for metastatic cancer and uses thereof |
EP3908215B1 (en) | 2019-01-11 | 2023-08-02 | Mayo Foundation for Medical Education and Research | Micro-invasive surgical device |
WO2022150837A1 (en) | 2021-01-08 | 2022-07-14 | Sonex Health, Inc. | Surgical cutting device for ultrasonic guided soft tissue surgery |
USD989961S1 (en) | 2021-04-30 | 2023-06-20 | Sonex Health, Inc. | Soft tissue cutting device |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US345143A (en) * | 1886-07-06 | Crupper press and former | ||
WO1998001755A1 (en) * | 1996-07-05 | 1998-01-15 | Fred Hutchinson Cancer Research Center | Screening method for mena protein involved in microfilament dynamics |
US5912128A (en) * | 1998-02-20 | 1999-06-15 | Incyte Pharmaceuticals, Inc. | Human ena/VASP-like protein splice variant |
US6716597B2 (en) * | 2000-04-03 | 2004-04-06 | Massachusetts Institute Of Technology | Methods and products for regulating cell motility |
US6632610B2 (en) * | 2000-10-12 | 2003-10-14 | Gensat S.A. | Methods of identification and isolation of polynucleotides containing nucleic acid differences |
US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
US20050244851A1 (en) | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
EP1784646B1 (en) * | 2004-08-11 | 2012-06-13 | Albert Einstein College Of Medicine Of Yeshiva University | Method for identifying metastasis in motile cells |
EP2126566B1 (en) | 2007-02-02 | 2017-03-29 | Albert Einstein College of Medicine, Inc. | Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors |
US20110296538A1 (en) * | 2008-10-30 | 2011-12-01 | Jeffrey Edward Segall | In vivo quantitative screening test for anti-metastasis treatment efficacy |
US8642277B2 (en) * | 2009-09-10 | 2014-02-04 | Albert Einstein College Of Medicine Of Yeshiva University | Tumor microenvironment of metastasis (TMEM) and uses thereof in diagnosis, prognosis and treatment of tumors |
US20120322685A1 (en) | 2010-01-25 | 2012-12-20 | Condeelis John S | Device for collecting and analyzing migratory tumor cells |
CA2788456A1 (en) | 2010-01-27 | 2011-08-04 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for determining agents targeting mena isoforms and uses thereof for diagnosis and treatment of metastatic tumors |
-
2008
- 2008-01-31 EP EP08713370.8A patent/EP2126566B1/en not_active Not-in-force
- 2008-01-31 CA CA2676179A patent/CA2676179C/en not_active Expired - Fee Related
- 2008-01-31 ES ES08713370.8T patent/ES2627011T3/es active Active
- 2008-01-31 WO PCT/US2008/001343 patent/WO2008097466A2/en active Application Filing
- 2008-01-31 DK DK08713370.8T patent/DK2126566T3/en active
-
2009
- 2009-07-31 US US12/462,324 patent/US8603738B2/en active Active
-
2013
- 2013-11-07 US US14/074,089 patent/US9719142B2/en active Active
-
2017
- 2017-07-27 US US15/661,021 patent/US20170335406A1/en not_active Abandoned
-
2021
- 2021-09-16 US US17/477,327 patent/US20220251662A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2126566A4 (en) | 2010-06-02 |
US8603738B2 (en) | 2013-12-10 |
WO2008097466A2 (en) | 2008-08-14 |
EP2126566A2 (en) | 2009-12-02 |
US9719142B2 (en) | 2017-08-01 |
WO2008097466A3 (en) | 2008-11-20 |
US20140057966A1 (en) | 2014-02-27 |
US20100047240A1 (en) | 2010-02-25 |
US20170335406A1 (en) | 2017-11-23 |
DK2126566T3 (en) | 2017-06-12 |
EP2126566B1 (en) | 2017-03-29 |
CA2676179A1 (en) | 2008-08-14 |
US20220251662A1 (en) | 2022-08-11 |
CA2676179C (en) | 2019-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2627011T3 (es) | Variantes de corte y empalme específicas de metástasis de Mena y usos de las mismas en el diagnóstico, pronóstico y tratamiento de tumores | |
Fong et al. | Lysyl oxidase‐like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors | |
ES2581841T3 (es) | Marcadores para la detección del cáncer gástrico | |
ES2861316T3 (es) | Métodos para pronosticar cáncer de próstata | |
US20040171037A1 (en) | Amplified genes involved in cancer | |
EP2867376A1 (en) | Targeted rna-seq methods and materials for the diagnosis of prostate cancer | |
US20030049645A1 (en) | Amplified cancer gene hepsin | |
ES2914727T3 (es) | Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata | |
WO2015049377A1 (en) | Method for determining the prognosis of pancreatic cancer | |
US20030175763A1 (en) | Identification of an amplified gene and target for drug intervention | |
US20050112678A1 (en) | Gene amplification and overexpression in cancer | |
US20050026194A1 (en) | Gene amplification and overexpression in cancer | |
WO2004015063A2 (en) | Amplification and overexpression of oncogenes | |
JP2007082433A (ja) | 悪性脳腫瘍マーカー遺伝子およびその用途 | |
EP1370693B1 (en) | Amplified cancer gene wip1 | |
Wang et al. | Analysis of progressively overexpressed genes in tumorigenesis of colorectal cancers using cDNA microarray | |
KR20220163765A (ko) | Bub1의 비근침윤성 방광암의 예후 예측용 바이오마커로의 용도 | |
Campos | Molecular characterization of novel candidate genes involved in the initiation of multiple primary melanomas | |
US20070105102A1 (en) | Method for detection and characterization of pre-malignant transformation | |
JP2007089547A (ja) | 脳腫瘍患者の予後を予測するための脳腫瘍マーカーおよびその用途 | |
WO2015144968A1 (es) | Método de predicción de respuesta al tratamiento de la leucemia linfoblástica aguda |